Board of Directors

English

Frédéric Cren, CEO

Frédéric Cren, an experienced pharmaceutical executive, is CEO and Co-Founder of Inventiva. He has held several key positions in the pharmaceutical industry, the most recent being General Manager – Research with Abbott Labs from 2010 to 2012. Mr. Cren has demonstrated his expertise in the areas of research, development, marketing, strategy and operations through his various roles as Vice-President Strategic Marketing, Vice-President US Operations and member of the Executive Committee of Fournier Laboratories from 2001 to 2005. During this period he was in charge of Fournier’s fenofibrate franchise and of the successful development and launch of TriCor® 145. He subsequently moved up to Head of Business Strategy and Portfolio, Senior Vice-President of the Research Division and member of the Executive Committee of Solvay Pharmaceuticals following the acquisition of Fournier by Solvay in 2005. Prior to joining the pharmaceutical industry, Mr. Cren was a consultant for 8 years with The Boston Consulting Group and a Manager in their healthcare practice. He holds an MBA from INSEAD, a MA from Johns Hopkins University and a Bachelor’s Degree from Paris IX Dauphine.

Pierre Broqua, Deputy General Manager

Dr Broqua brings over 25 years of experience in drug discovery and innovative research to Inventiva. Before co-founding Inventiva, he successfully managed numerous research programs leading to the discovery of highly innovative preclinical and clinical compounds, in particular during his tenure at Ferring Pharmaceuticals from 1997 to 2002 and Fournier Laboratories from 2002 to 2005, as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010 and finally as Head of Research for the Abbott Dijon R&D site. One of his most notable achievements was his co-discovery, while head of Pharmacology at Ferring Pharmaceuticals, of the GnRH antagonist Degarelix (now marketed under the brand name Firmagon®). Dr Broqua holds a Ph.D in Pharmacology from the University of Paris Descartes and has a master’s degree in Chemistry and Biochemistry from Université Pierre et Marie Curie, Paris.

Karen Aiach, Independent director

Karen Aiach is the founder and CEO of Lysogene, a pioneering and listed biotechnology company active in fundamental research and the clinical development of gene therapies for central nervous system diseases. Karen has extensive business acumen having begun her career with Arthur Andersen, where she worked for seven years in audit services and international transactions, before setting up and running her own financial services firm. Karen has also served as a patient representative and member of the Paediatric Committee of the European Medicines Agency (EMA). She is a founding and executive member of the International Rare Diseases Research Consortium (IRDiRC). Karen holds a DEA postgraduate diploma from University of Paris VIII and is a graduate of ESSEC Business School.

Chris Buyse, Independent director

Chris Buyse possesses more than 30 years’ expertise in international finance and financial management. He was CFO of CropDesign, a Belgian company of which he coordinated the acquisition by BASF, and CFO of ThromboGenics, a biotechnology company listed on the New York Stock Exchange and on Euronext Brussels. He has also held various positions with Spector Photo Group, Lyonnaise des Eaux (Suez) and Unilever. He currently holds a Director position in several private and public companies. Chris gained a master’s degree in applied economic science from the University of Antwerp and a MBA from the Vlerick School of Management in Ghent.

Nanna Lüneborg, Director

Nanna Lüneborg is a Principal at Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ in January 2017. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.

Nanna holds a BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA from University of Cambridge, where she was a Sainsbury Scholar.

Jean-Louis Junien, Director

Jean-Louis Junien held various senior management positions in the pharmaceutical industry, first as Director of Jouveinal Research Institute and General Manager of Jouveinal Laboratoires, then as Vice President Research and Development Jouveinal-Warnert Lambert, followed by positions as Director of the Ferring Research Institutes in Southampton (United Kingdom) and La Jolla (United States) and Global CSO for Ferring Pharmaceuticals. From 2001 to 2007, he was CSO of Laboratoires Fournier. He founded ISLS Consulting in 2007 and has been working with Inventiva since 2012.

Chris Newton, Independent director

Chris Newton was in 2000 a founding member and Chief Scientific Officer of Argenta Discovery. At moving to BioFocus plc in 2005, Chris was a director and Chief Scientific Officer. He was then appointed Senior Vice-President of Galapagos Services, managing the services business of Galapagos after the acquisition of BioFocus by Galapagos. Previously Chris held several senior positions within Rhône-Poulenc/Aventis R&D organization. Chris holds an MA degree from the University of Cambridge and MSc and PhD degrees from the Univeristy of Sheffield, and is also a Chartered Chemist and Fellow of the Royal Society of Chemistry.

Annick Schwebig, Independent director

Annick Schwebig was the founder and Chairman and Chief Executive Officer of Actelion Pharmaceuticals France, a pharmaceuticals company specialized in developing drugs for orphan diseases, and has held senior positions in the pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb. Annick has been a member of Cellectis’ Board of Directors since 2011. Annick is a graduate of the Paris Faculty of Medicine.